Cite
HARVARD Citation
Jackson, D. et al. (n.d.). Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine. Journal for immunotherapy of cancer. p. . [Online].